MedTrace Logo

The Glycocalyx in COVID-19 Patients. A Pilot Study

NCT05137249 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-11-30

No results posted yet for this study

Summary

The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS. We aim to generate first hints regarding the impact of covid-19 disease on the (damage) of the endothelial glycocalyx. Furthermore, we want to investigate the potential coagulopathies, which go along with shedding of the glycocalyx. The detection of and the relation between the severity of the disease, as well as the extent of the glycocalyx damage during the observational period, as well as the hemostatic alterations, are aim of the study.

Conditions

  • COVID-19
  • Endothelial Dysfunction
  • Coagulation Disorder

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Judith Schiefer, MD PhD · Medical University of Vienna, Department of Anesthesia, Intensive Care Medicine and Pain Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-03-01
Completion
2021-05-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137249 on ClinicalTrials.gov